Year: 2023

generic_link-22

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplusâ„¢ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases